Data / Form D filings / SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.: Form D filings
SELLAS Life Sciences Group, Inc., a biotechnology company in New York, NY, filed 5 Form D notices with the SEC between 2014 and 2024. The latest, on March 29, 2024, reports $18.4 million sold of a $18.4 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7 TIMES SQUARE, SUITE 2503, New York, NY, 10036
- Phone
- (646) 200-5278
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1390478
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 29, 2024 | New notice | $18,371,336 | $18,371,336 | 4 | Mar 15, 2024 | sec.gov | |
| Aug 31, 2020 | New notice | $9,151,500 | $9,151,500 | 11 | Jul 31, 2020 | sec.gov | |
| Jul 26, 2016 | New notice | $9,100,000 | $9,100,000 | 3 | Jul 13, 2016 | sec.gov | |
| May 24, 2016 | New notice | $24,000,000 | $24,000,000 | 1 | May 10, 2016 | sec.gov | |
| Jan 22, 2014 | New notice | Indefinite | $0 | 4 | Jan 12, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jane Van Wasman | Director | |
| Angelos M. Stergiou | Executive Officer, Director | |
| David A. Scheinberg | Director | |
| John T. Burns | Executive Officer | |
| John Van Varian | Director | |
| Robert Van Nostrand | Director | |
| Katherine Bach Kalin | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Mar 25, 2024 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what SELLAS Life Sciences Group, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.